Loading…

Differential Responses to UVB Irradiation in Human Keratinocytes and Epidermoid Carcinoma Cells

Abstract Objective To examine UVB-induced responses in normal human keratinocytes (HaCaT) and epidermoid carcinoma cells (A431) at the cellular and molecular level, and investigated the protective effect of salidroside. Methods Cells irradiated by UVB at various dosage and their viability was assess...

Full description

Saved in:
Bibliographic Details
Published in:Biomedical and environmental sciences 2012-10, Vol.25 (5), p.583-589
Main Authors: ZHOU, Mei Juan, ZHENG, Li, GUO, Ling, LIU, Wei Ling, LV, Chao, JIANG, Li Hong, OU, Cheng Shan, DING, Zhen Hua
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To examine UVB-induced responses in normal human keratinocytes (HaCaT) and epidermoid carcinoma cells (A431) at the cellular and molecular level, and investigated the protective effect of salidroside. Methods Cells irradiated by UVB at various dosage and their viability was assessed by MTT assays, cell cycle was analysed by flow cytometry. The expression of NF-KB, BCL-2, and CDK6 after 50 J/㎡ UVB irradiation were detected by RT-PCR and western blotting. Results Our results confirmed greater tolerance of A341 cells to UVB-induced damage such as cell viability and cell cycle arrest, which was accompanied by differential expression changes in NF-KB, BCL-2, and CDK6. UVB exposure resulted in HaCaT cells undergoing G1-S phase arrest. When treated with salidroside, HaCaT survival was significantly enhanced following exposure to UVB, suggesting great therapeutic potential for this compound. Conclusion Taken together, our study suggests that A431 respond differently to UVB than norma HaCaT cells, and supports a role for NF-KB, CDK6, and BCL-2 in UVB-induced cell G1-S phase arrest Furthermore, salidroside can effectively protect HaCaT from UVB irradiation.
ISSN:0895-3988
2214-0190
DOI:10.3967/0895-3988.2012.05.013